Clinical Biomarkers of Dyslipidemia
Publisher
Springer Singapore
Reference45 articles.
1. Marcovina S, Packard CJ. Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Intern Med. 2006;259:437–46.
2. Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4:337–45.
3. Sniderman AD, Islam S, McQueen M, et al. Age and cardiovascular risk attributable to apolipoprotein B, low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol. J Am Heart Assoc. 2016 Oct 13;5(10):e003665.
4. Sniderman AD, Tremblay A, De Graaf J, et al. Phenotypes of hypertriglyceridemia caused by excess very-low-density lipoprotein. J Clin Lipidol. 2012;6:427–33.
5. McQueen MJ, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infection in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372:224–33.